For example, intratumoral XCLI injection enhances CD8+CTLs’ antitumor activity by recruiting CXCL9 (a ligand for CXCR3) and XCR1-expressing conventional type 1 DCs, which, by interacting with CTLs (CD8+T and NK cells) increase their antitumor action in melanoma [457]. Here, CD8A is linked to melanoma.